2024 annual financial data

Alnylam Pharmaceuticals 2024 Financial results

Direct answer

Revenue was 2,248,243,000 USD.

Operating income was -176,885,000 USD and net income was -278,157,000 USD.
Operating cash flow was -8,312,000 USD.

Get free Alnylam Pharmaceuticals email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
2,248,243,000 USD
Operating income
-176,885,000 USD
Net income
-278,157,000 USD
Operating cash flow
-8,312,000 USD